Biodesix Price To Sales Ratio vs Free Cash Flow Yield Analysis

BDSX Stock

USD 7.74 0.04 0.52%

Biodesix financial indicator trend analysis is way more than just evaluating Biodesix prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biodesix is a good investment. Please check the relationship between Biodesix Price To Sales Ratio and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodesix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Biodesix Stock please use our How to Invest in Biodesix guide.

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biodesix Price To Sales Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Biodesix's Price To Sales Ratio and Free Cash Flow Yield is 0.89. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Biodesix, assuming nothing else is changed. The correlation between historical values of Biodesix's Price To Sales Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Biodesix are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Price To Sales Ratio i.e., Biodesix's Price To Sales Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Biodesix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Biodesix sales, a figure that is much harder to manipulate than other Biodesix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Biodesix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biodesix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodesix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Biodesix Stock please use our How to Invest in Biodesix guide.Selling General Administrative is likely to drop to about 55.2 M in 2025. Issuance Of Capital Stock is likely to drop to about 43.9 M in 2025

	2024	2025 (projected)
Depreciation And Amortization	5.5M	4.0M
Interest Income	16.2K	25.9K

Depreciation And Amortization Interest Income

Biodesix fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.56	0.69	0.85	0.96	-0.4	0.96	0.67	0.62	-0.33	-0.79	0.76	0.94	0.75	0.88	0.87	0.17	0.94	0.9	0.93	0.95	0.58	-0.94	0.83	0.98	0.93
Short Long Term Debt Total	0.56		0.43	0.42	0.47	-0.4	0.49	0.86	-0.12	0.53	-0.76	0.23	0.27	0.91	0.8	0.75	0.88	0.27	0.53	0.62	0.54	0.78	-0.43	0.1	0.48	0.64
Other Current Liab	0.69	0.43		0.84	0.78	-0.7	0.8	0.63	0.21	-0.14	-0.73	0.24	0.59	0.68	0.71	0.69	0.13	0.59	0.41	0.74	0.79	0.45	-0.82	0.59	0.73	0.8
Total Current Liabilities	0.85	0.42	0.84		0.83	-0.3	0.83	0.54	0.64	-0.32	-0.67	0.66	0.82	0.58	0.68	0.69	-0.02	0.82	0.78	0.8	0.83	0.39	-0.84	0.81	0.85	0.78
Total Stockholder Equity	0.96	0.47	0.78	0.83		-0.59	1.0	0.69	0.54	-0.34	-0.84	0.6	0.91	0.74	0.87	0.89	0.1	0.91	0.76	0.96	0.99	0.62	-0.99	0.85	0.98	0.96
Other Liab	-0.4	-0.4	-0.7	-0.3	-0.59		-0.6	-0.68	0.28	-0.17	0.74	0.27	-0.24	-0.66	-0.64	-0.65	-0.36	-0.24	0.0	-0.63	-0.63	-0.64	0.61	-0.24	-0.47	-0.69
Net Tangible Assets	0.96	0.49	0.8	0.83	1.0	-0.6		0.7	0.52	-0.33	-0.84	0.6	0.9	0.75	0.88	0.89	0.13	0.9	0.76	0.96	0.99	0.62	-0.99	0.84	0.98	0.97
Property Plant And Equipment Net	0.67	0.86	0.63	0.54	0.69	-0.68	0.7		-0.06	0.44	-0.95	0.19	0.41	0.94	0.84	0.9	0.69	0.41	0.51	0.78	0.77	0.96	-0.64	0.33	0.65	0.78
Current Deferred Revenue	0.62	-0.12	0.21	0.64	0.54	0.28	0.52	-0.06		-0.74	-0.12	0.87	0.78	-0.01	0.19	0.22	-0.54	0.78	0.76	0.46	0.48	-0.07	-0.54	0.85	0.63	0.36
Net Debt	-0.33	0.53	-0.14	-0.32	-0.34	-0.17	-0.33	0.44	-0.74		-0.21	-0.53	-0.6	0.3	0.02	0.07	0.76	-0.6	-0.3	-0.17	-0.23	0.49	0.39	-0.63	-0.38	-0.17
Retained Earnings	-0.79	-0.76	-0.73	-0.67	-0.84	0.74	-0.84	-0.95	-0.12	-0.21		-0.27	-0.6	-0.9	-0.9	-0.97	-0.52	-0.6	-0.58	-0.9	-0.9	-0.91	0.8	-0.5	-0.78	-0.9
Accounts Payable	0.76	0.23	0.24	0.66	0.6	0.27	0.6	0.19	0.87	-0.53	-0.27		0.82	0.29	0.42	0.41	-0.16	0.82	0.93	0.53	0.55	0.13	-0.58	0.77	0.72	0.49
Cash	0.94	0.27	0.59	0.82	0.91	-0.24	0.9	0.41	0.78	-0.6	-0.6	0.82		0.49	0.71	0.72	-0.13	1.0	0.86	0.82	0.87	0.34	-0.9	0.9	0.93	0.81
Non Current Assets Total	0.75	0.91	0.68	0.58	0.74	-0.66	0.75	0.94	-0.01	0.3	-0.9	0.29	0.49		0.94	0.89	0.72	0.49	0.58	0.82	0.78	0.84	-0.71	0.37	0.72	0.86
Non Currrent Assets Other	0.88	0.8	0.71	0.68	0.87	-0.64	0.88	0.84	0.19	0.02	-0.9	0.42	0.71	0.94		0.95	0.56	0.71	0.68	0.91	0.89	0.75	-0.85	0.51	0.84	0.95
Other Assets	0.87	0.75	0.69	0.69	0.89	-0.65	0.89	0.9	0.22	0.07	-0.97	0.41	0.72	0.89	0.95		0.51	0.72	0.68	0.92	0.92	0.85	-0.84	0.55	0.83	0.92
Long Term Debt	0.17	0.88	0.13	-0.02	0.1	-0.36	0.13	0.69	-0.54	0.76	-0.52	-0.16	-0.13	0.72	0.56	0.51		-0.13	0.12	0.26	0.18	0.66	-0.06	-0.35	0.08	0.32
Cash And Short Term Investments	0.94	0.27	0.59	0.82	0.91	-0.24	0.9	0.41	0.78	-0.6	-0.6	0.82	1.0	0.49	0.71	0.72	-0.13		0.86	0.82	0.87	0.34	-0.9	0.9	0.93	0.81
Net Receivables	0.9	0.53	0.41	0.78	0.76	0.0	0.76	0.51	0.76	-0.3	-0.58	0.93	0.86	0.58	0.68	0.68	0.12	0.86		0.76	0.75	0.45	-0.73	0.78	0.85	0.71
Good Will	0.93	0.62	0.74	0.8	0.96	-0.63	0.96	0.78	0.46	-0.17	-0.9	0.53	0.82	0.82	0.91	0.92	0.26	0.82	0.76		0.98	0.73	-0.95	0.77	0.95	0.98
Common Stock Total Equity	0.95	0.54	0.79	0.83	0.99	-0.63	0.99	0.77	0.48	-0.23	-0.9	0.55	0.87	0.78	0.89	0.92	0.18	0.87	0.75	0.98		0.71	-0.98	0.81	0.96	0.97
Common Stock Shares Outstanding	0.58	0.78	0.45	0.39	0.62	-0.64	0.62	0.96	-0.07	0.49	-0.91	0.13	0.34	0.84	0.75	0.85	0.66	0.34	0.45	0.73	0.71		-0.55	0.28	0.57	0.69
Non Current Liabilities Total	-0.94	-0.43	-0.82	-0.84	-0.99	0.61	-0.99	-0.64	-0.54	0.39	0.8	-0.58	-0.9	-0.71	-0.85	-0.84	-0.06	-0.9	-0.73	-0.95	-0.98	-0.55		-0.86	-0.97	-0.96
Inventory	0.83	0.1	0.59	0.81	0.85	-0.24	0.84	0.33	0.85	-0.63	-0.5	0.77	0.9	0.37	0.51	0.55	-0.35	0.9	0.78	0.77	0.81	0.28	-0.86		0.89	0.72
Other Current Assets	0.98	0.48	0.73	0.85	0.98	-0.47	0.98	0.65	0.63	-0.38	-0.78	0.72	0.93	0.72	0.84	0.83	0.08	0.93	0.85	0.95	0.96	0.57	-0.97	0.89		0.94
Other Stockholder Equity	0.93	0.64	0.8	0.78	0.96	-0.69	0.97	0.78	0.36	-0.17	-0.9	0.49	0.81	0.86	0.95	0.92	0.32	0.81	0.71	0.98	0.97	0.69	-0.96	0.72	0.94

Click cells to compare fundamentals

Biodesix Account Relationship Matchups

Biodesix fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	121.1M	76.1M	92.9M	99.1M	97.2M	89.1M
Short Long Term Debt Total	27.8M	10.0M	31.9M	60.7M	62.0M	39.5M
Other Current Liab	7.8M	25.4M	18.6M	29.9M	9.9M	16.0M
Total Current Liabilities	32.1M	29.0M	22.8M	33.4M	14.3M	24.9M
Total Stockholder Equity	41.2M	19.7M	20.6M	4.6M	20.9M	21.9M
Other Liab	29.8M	31.9M	17.4M	19.2M	17.3M	19.8M
Net Tangible Assets	(255.3M)	12.9M	(6.9M)	(4.2M)	(4.9M)	(5.1M)
Property Plant And Equipment Net	3.2M	4.2M	8.8M	29.6M	29.6M	31.1M
Current Deferred Revenue	3.5M	1.9M	962K	324K	678K	1.0M
Net Debt	(34.4M)	(22.7M)	(11.2M)	34.4M	35.7M	37.5M
Retained Earnings	(258.8M)	(302.0M)	(367.4M)	(419.6M)	(462.5M)	(485.6M)
Accounts Payable	9.0M	1.7M	1.7M	2.9M	2.2M	2.3M
Cash	62.1M	32.7M	43.1M	26.3M	26.2M	31.7M
Non Current Assets Total	34.9M	32.5M	39.6M	59.4M	57.8M	44.4M
Non Currrent Assets Other	3.5M	1.7M	5.9M	6.9M	7.3M	4.0M
Other Assets	90K	3.5M	1.7M	5.9M	6.8M	7.2M
Long Term Debt	15.9M	10.0M	25.0M	35.2M	36.4M	26.6M
Cash And Short Term Investments	62.1M	32.7M	43.1M	26.3M	26.2M	31.7M
Net Receivables	15.3M	3.7M	5.1M	7.7M	8.6M	7.5M
Common Stock Shares Outstanding	1.3M	1.4M	2.1M	4.1M	6.5M	6.8M
Liabilities And Stockholders Equity	121.1M	76.1M	92.9M	99.1M	97.2M	89.1M
Non Current Liabilities Total	47.8M	27.4M	49.5M	61.1M	62.1M	83.2M
Inventory	800K	3.2M	2.9M	1.4M	1.6M	1.9M
Other Current Assets	5.5M	4.3M	3.8M	4.3M	4.6M	4.0M
Other Stockholder Equity	300.0M	321.7M	387.9M	424.1M	483.2M	302.8M
Total Liab	79.9M	56.4M	72.3M	94.5M	76.4M	101.3M
Net Invested Capital	68.9M	29.7M	45.7M	39.9M	57.3M	60.2M
Property Plant And Equipment Gross	3.2M	4.2M	8.8M	35.2M	38.7M	40.7M
Total Current Assets	86.1M	43.6M	53.3M	39.7M	39.5M	44.8M
Capital Stock	27K	31K	78K	96K	145K	152.3K
Non Current Liabilities Other	31.9M	17.4M	19.2M	712K	815K	774.3K
Net Working Capital	54.0M	14.7M	30.5M	6.3M	25.2M	19.8M
Intangible Assets	13.3M	11.6M	9.8M	7.9M	5.9M	9.2M
Common Stock	27K	31K	78K	96K	145K	152.3K
Property Plant Equipment	2.1M	3.2M	4.2M	8.8M	10.1M	10.7M
Short Long Term Debt	11.8M	19K	49K	51K	21K	20.0K
Short Term Debt	11.8M	19K	1.6M	303K	1.5M	1.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
V	Visa Class A
C	Citigroup

Additional Tools for Biodesix Stock Analysis

When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Biodesix Price To Sales Ratio vs Free Cash Flow Yield Analysis

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Yield

Biodesix fundamental ratios Correlations

Biodesix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biodesix fundamental ratios Accounts

Also Currently Popular

Additional Tools for Biodesix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Common Stock Total Equity	+ 0.99	Total Stockholder Equity
Common Stock Total Equity	+ 0.99	Net Tangible Assets
Other Current Assets	+ 0.98	Total Assets
Other Current Assets	+ 0.98	Total Stockholder Equity

Non Current Liabilities Total	- 0.99	Net Tangible Assets
Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.98	Common Stock Total Equity
Other Current Assets	- 0.97	Non Current Liabilities Total
Other Assets	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Non Current Liabilities Total